Citation Report
List of articles citing

Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation

DOI: 10.1016/j.molcel.2017.10.010
Molecular Cell, 2017, 68, 591-604.e5.

Source: https://exaly.com/paper-pdf/66832714/citation-report.pdf
Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
169	Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression. **2018**, 50, 175-187		23
168	Hippo Signaling: Key Emerging Pathway in Cellular and Whole-Body Metabolism. **2018**, 29, 492-509		60
167	Regulation of the Hippo pathway in cancer biology. **2018**, 75, 2303-2319		42
166	The history and regulatory mechanism of the Hippo pathway. **2018**, 51, 106-118		28
165	The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC. **2018**, 37, 188-204		21
164	Metabolite sensing and signaling in cell metabolism. **2018**, 3, 30		68
163	O-GlcNAc as an Integrator of Signaling Pathways. **2018**, 9, 599		50
162	Emerging roles of YAP/TAZ in lung physiology and diseases. **2018**, 214, 176-183		21
161	O-GlcNAc-modified SNAP29 inhibits autophagy-mediated degradation via the disturbed SNAP29-STX17-VAMP8 complex and exacerbates myocardial injury in type I diabetic rats. **2018**, 42, 3278-3290		13
160	The Hippo Signaling Network and Its Biological Functions. **2018**, 52, 65-87		166
159	The role of YAP/TAZ activity in cancer metabolic reprogramming. **2018**, 17, 134		58
158	SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis. **2018**, 34, 103-118.e9		70
157	Metabolic Signaling to the Nucleus in Cancer. *Molecular Cell*, **2018**, 71, 398-408	17.6	78
156	Interplay between YAP/TAZ and Metabolism. **2018**, 28, 196-206		137
155	YAP/TAZ upstream signals and downstream responses. **2018**, 20, 888-899		350
154	YAP/TAZ Activation as a Target for Treating Metastatic Cancer. *Cancers*, **2018**, 10,	6.6	87
153	Catalytic deficiency of O-GlcNAc transferase leads to X-linked intellectual disability. **2019**, 116, 14961-14970		28

152	The Hippo Signaling Pathway in Development and Disease. **2019**, 50, 264-282		254
151	ERK Regulates HIF1Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. **2019**, 25, 5947-5960		19
150	Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. **2019**, 25, 1797-1816		14
149	Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. **2019**, 17, 52		106
148	YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine. **2019**, 9,		13
147	Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the mA reader YTHDF3. **2019**, 18, 143		202
146	Yes-Associated Protein (YAP) Facilitates Pressure Overload-Induced Dysfunction in the Diabetic Heart. **2019**, 4, 611-622		13
145	Differential Levels of Hippo Signaling in Selected Brain and Peripheral Tissues in Streptozotocin-Induced Cognitive Dysfunction in Mice. **2019**, 421, 48-58		2
144	Hippo signalling during development. **2019**, 146,		32
143	Glucose Metabolism in Pancreatic Cancer. *Cancers*, **2019**, 11,	6.6	33
142	Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation. **2019**, 33, 1783-1796		25
141	A novel YAP1/SLC35B4 regulatory axis contributes to proliferation and progression of gastric carcinoma. *Cell Death and Disease*, **2019**, 10, 452	9.8	11
140	Metastatic Colorectal Cancer Rewrites Metabolic Program Through a Glut3-YAP-dependent Signaling Circuit. **2019**, 9, 2526-2540		36
139	O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability. **2019**, 9, 3410-3424		23
138	YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells. **2019**, 49, 425-443.e9		35
137	Essential role of O-GlcNAcylation in stabilization of oncogenic factors. **2019**, 1863, 1302-1317		23
136	Life is sweet: the cell biology of glycoconjugates. **2019**, 30, 525-529		6
135	Dysregulation of the Hippo pathway signaling in aging and cancer. **2019**, 143, 151-165		18

134	YAP/TAZ Signaling and Resistance to Cancer Therapy. **2019**, 5, 283-296		83
133	YAPping about and not forgetting TAZ. **2019**, 593, 253-276		19
132	The Hippo Pathway: Biology and Pathophysiology. **2019**, 88, 577-604		253
131	An Isotope-Coded Photocleavable Probe for Quantitative Profiling of Protein O-GlcNAcylation. **2019**, 14, 4-10		33
130	The posttranslational modifications of Hippo-YAP pathway in cancer. **2020**, 1864, 129397		15
129	The emerging role of Hippo signaling in neurodegeneration. **2020**, 98, 796-814		20
128	Hippo-Yap/Taz signaling: Complex network interactions and impact in epithelial cell behavior. **2020**, 9, e371		7
127	AMPK1 and AMPK2 define an isoform-specific gene signature in human pluripotent stem cells, differentially mediating cardiac lineage specification. *Journal of Biological Chemistry*, **2020**, 295, 17659-17671	5.4	2
126	Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. **2020**, 9,		47
125	Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion. *Cell Death and Disease*, **2020**, 11, 815	9.8	6
124	OGT knockdown counteracts high phosphate-induced vascular calcification in chronic kidney disease through autophagy activation by downregulating YAP. **2020**, 261, 118121		4
123	Integration of Hippo-YAP Signaling with Metabolism. **2020**, 54, 256-267		17
122	Metabolites Regulate Cell Signaling and Growth via Covalent Modification of Proteins. **2020**, 54, 156-170		28
121	MST4 kinase suppresses gastric tumorigenesis by limiting YAP activation via a non-canonical pathway. *Journal of Experimental Medicine*, **2020**, 217,	16.6	15
120	Mechanosensing through YAP controls T cell activation and metabolism. *Journal of Experimental Medicine*, **2020**, 217,	16.6	14
119	Molecular Mechanism of Hippo-YAP1/TAZ Pathway in Heart Development, Disease, and Regeneration. **2020**, 11, 389		18
118	A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations. *Frontiers in Oncology*, **2020**, 10, 928	5.3	25
117	Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases. **2020**, 159, 105009		7

116	-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity. **2020**, 117, 14259-14269		15
115	O-GlcNAcylation Dampens Dpp/BMP Signaling to Ensure Proper Drosophila Embryonic Development. **2020**, 53, 330-343.e3		5
114	YAP nuclear-cytoplasmic translocation is regulated by mechanical signaling, protein modification, and metabolism. **2020**, 44, 1416-1425		11
113	Glycolysis-Independent Glucose Metabolism Distinguishes TE from ICM Fate during Mammalian Embryogenesis. **2020**, 53, 9-26.e4		33
112	-GlcNAcase contributes to cognitive function in. *Journal of Biological Chemistry*, **2020**, 295, 8636-8646	5.4	6
111	Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. **2020**, 39, 13		11
110	Mechanisms of the Epithelial-Mesenchymal Transition and Tumor Microenvironment in -Induced Gastric Cancer. **2020**, 9,		43
109	Living a Sweet Life: Glucose Instructs Cell Fate in the Mouse Embryo. **2020**, 53, 1-2		9
108	The nutrient sensor OGT regulates Hipk stability and tumorigenic-like activities in. **2020**, 117, 2004-2013		7
107	Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation. **2021**, 11, 805-823		7
106	Role of -Linked -Acetylglucosamine Protein Modification in Cellular (Patho)Physiology. **2021**, 101, 427-493		32
105	YAP and TAZ Are Not Identical Twins. **2021**, 46, 154-168		26
104	The Hippo Pathway in Liver Homeostasis and Pathophysiology. **2021**, 16, 299-322		25
103	Transcriptional co-activators YAP/TAZ: Potential therapeutic targets for metastatic breast cancer. *Biomedicine and Pharmacotherapy*, **2021**, 133, 110956	7.5	5
102	O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene?. **2021**, 19, 555-564		8
101	YAP in pancreatic cancer: oncogenic role and therapeutic strategy. **2021**, 11, 1753-1762		5
100	Analytical and Biochemical Perspectives of Protein O-GlcNAcylation. **2021**, 121, 1513-1581		21
99	Targeting the Hippo Pathway in Prostate Cancer: What'ѕ New?. *Cancers*, **2021**, 13,	6.6	7

98	Research progress on O-GlcNAcylation in the occurrence, development, and treatment of colorectal cancer. **2021**, 13, 96-115		
97	YAP and TAZ Mediators at the Crossroad between Metabolic and Cellular Reprogramming. **2021**, 11,		3
96	GREB1: An evolutionarily conserved protein with a glycosyltransferase domain links ER glycosylation and stability to cancer. **2021**, 7,		4
95	O-GlcNAcylation and O-GlcNAc Cycling Regulate Gene Transcription: Emerging Roles in Cancer. *Cancers*, **2021**, 13,	6.6	19
94	Hippo-Independent Regulation of Yki/Yap/Taz: A Non-canonical View. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 658481	5.7	5
93	O-GlcNAcylation enhances sensitivity to RSL3-induced ferroptosis via the YAP/TFRC pathway in liver cancer. *Cell Death Discovery*, **2021**, 7, 83	6.9	8
92	Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation. **2021**, 131,		12
91	Yap regulates skeletal muscle fatty acid oxidation and adiposity in metabolic disease. *Nature Communications*, **2021**, 12, 2887	17.4	3
90	Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation. *Molecular Cell*, **2021**, 81, 1890-1904.e7	17.6	8
89	O-GlcNAcylation is a key regulator of multiple cellular metabolic pathways. 9, e11443		
88	N-Myristoylation by NMT1 Is POTEE-Dependent to Stimulate Liver Tumorigenesis Differentially Regulating Ubiquitination of Targets. *Frontiers in Oncology*, **2021**, 11, 681366	5.3	1
87	Revisiting the Hayflick Limit: Insights from an Integrated Analysis of Changing Transcripts, Proteins, Metabolites and Chromatin.		0
86	High Glucose Activates YAP Signaling to Promote Vascular Inflammation. **2021**, 12, 665994		2
85	OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP. **2021**, 40, 4859-4871		4
84	Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer. *Cancer Letters*, **2021**, 507, 112-123	9.9	10
83	An Updated Understanding of the Role of YAP in Driving Oncogenic Responses. *Cancers*, **2021**, 13,	6.6	5
82	pVHL promotes lysosomal degradation of YAP in lung adenocarcinoma. *Cellular Signalling*, **2021**, 83, 110002	4.9	0
81	YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. **2021**, 475, 205-221		12

80	Metabolic reprogramming in cancer: mechanistic insights from Drosophila. **2021**, 14, 1-17		1
79	Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP/TAZ. **2021**,		7
78	Yes-Associated Protein in Atherosclerosis and Related Complications: A Potential Therapeutic Target That Requires Further Exploration. **2021**, 8, 704208		0
77	DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation. **2021**, 36, 109739		6
76	O-GlcNAcylation inhibits hepatic stellate cell activation. **2021**,		2
75	Targeting the Hippo pathway in heart repair. **2021**,		3
74	Role of Hexosamine Biosynthetic Pathway on Cancer Stem Cells: Connecting Nutrient Sensing to Cancer Cell Plasticity. **2021**,		
73	Loss of O-GlcNAcase catalytic activity leads to defects in mouse embryogenesis. *Journal of Biological Chemistry*, **2021**, 296, 100439	5.4	6
72	Regulation and functions of the Hippo pathway in stemness and differentiation. **2020**, 52, 736-748		7
71	O-GlcNAc modification of oncogenic transcription factor Sox2 promotes protein stability and regulates self-renewal in pancreatic cancer.		3
70	O-glycosylation regulates plant developmental transitions downstream of miR156.		1
69	LDL receptor-related protein LRP6 senses nutrient levels and regulates Hippo signaling. *EMBO Reports*, **2020**, 21, e50103	6.5	8
68	Glycogen accumulation and phase separation drives liver tumor initiation. *Cell*, **2021**, 184, 5559-5576.e19	36.2	16
67	The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. *SSRN Electronic Journal*,	1	2
66	Tissue mechanics controls T-cell activation and metabolism.		
65	Regulation of BMP Signaling by O-GlcNAcylation.		
64	Glucose metabolism distinguishes TE from ICM fate during mammalian embryogenesis.		1
63	Loss of O-GlcNAcylation on MeCP2 Thr 203 Leads to Neurodevelopmental Disorders.		

62	Methyl-CpG-binding domain 3 inhibits stemness of pancreatic cancer cells via Hippo signaling. *Experimental Cell Research*, **2020**, 393, 112091	4.2	4
61	Gluconeogenic Enzyme PCK1 Deficiency Is Critical for CHK2 O-GlcNAcylation and Hepatocellular Carcinoma Growth upon Glucose Deprivation.		
60	LRP6 lets Merlin go in times of nutrient scarcity. *EMBO Reports*, **2020**, 21, e51358	6.5	1
59	O-GlcNAcylation of SAMHD1 Indicating a Link between Metabolic Reprogramming and Anti-HBV Immunity.		
58	Metabolic sensor O-GlcNAcylation regulates megakaryopoiesis and thrombopoiesis through c-Myc stabilization and integrin perturbation. *Stem Cells*, **2021**, 39, 787-802	5.8	3
57	Metabolic sensor O- GlcNAcylation regulates megakaryopoiesis and thrombopoiesis through c-Myc stabilization and integrin perturbation. *Stem Cells*, **2021**, 39, 787-802	5.8	4
56	O-GlcNAcylation regulation of cellular signaling in cancer. *Cellular Signalling*, **2021**, 90, 110201	4.9	2
55	Loss of O-GlcNAcylation on MeCP2 at Threonine 203 Leads to Neurodevelopmental Disorders. *Neuroscience Bulletin*, **2021**, 38, 113	4.3	0
54	A narrative review for the Hippo-YAP pathway in cancer survival and immunity: the Yin-Yang dynamics.. *Translational Cancer Research*, **2022**, 11, 262-275	0.3	0
53	Context-dependent transcriptional regulations of YAP/TAZ in stem cell and differentiation.. *Stem Cell Research and Therapy*, **2022**, 13, 10	8.3	3
52	Context-dependent transcriptional regulations of YAP/TAZ in cancer.. *Cancer Letters*, **2021**, 527, 164-173	9.9	0
51	TGF Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGF nduced EMT in PDAC.. *Cancers*, **2021**, 13,	6.6	2
50	Role of Hippo signaling pathway in occurrence, development, and treatment of primary hepatocellular carcinoma. *World Chinese Journal of Digestology*, **2022**, 30, 34-42	0.1	
49	Regulation of Hippo signaling by metabolic pathways in cancer.. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2022**, 1869, 119201	4.9	0
48	A chemical method for genome- and proteome-wide enrichment and O-GlcNAcylation profiling of chromatin-associated proteins.. *Talanta*, **2021**, 241, 123167	6.2	0
47	YAP ISGylation increases its stability and promotes its positive regulation on PPP by stimulating 6PGL transcription.. *Cell Death Discovery*, **2022**, 8, 59	6.9	1
46	Novel insights from a multiomics dissection of the hayflick limit.. *ELife*, **2022**, 11,	8.9	0
45	Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer.. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 793428	5.7	6

44	YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. *Advances in Cancer Research*, **2022**,	5.9	0
43	Some Insights into the Regulation of Cardiac Physiology and Pathology by the Hippo Pathway.. *Biomedicines*, **2022**, 10,	4.8	1
42	Metabolic determinants of cardiomyocyte proliferation.. *Stem Cells*, **2022**,	5.8	1
41	YAP Targets the TGF Pathway to Mediate High-Fat/High-Sucrose Diet-Induced Arterial Stiffness.. *Circulation Research*, **2022**, CIRCRESAHA121320464	15.7	1
40	O-GlcNAc transferase promotes the nuclear localization of the focal adhesion-associated protein Zyxin to regulate UV-induced cell death.. *Journal of Biological Chemistry*, **2022**, 101776	5.4	0
39	OGT as potential novel target: Structure, function and inhibitors.. *Chemico-Biological Interactions*, **2022**, 109886	5	3
38	KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling.. *Nature Communications*, **2022**, 13, 2192	17.4	0
37	O-GlcNAcylation and stablization of SIRT7 promote pancreatic cancer progression by blocking the SIRT7-REG interaction.. *Cell Death and Differentiation*, **2022**,	12.7	0
36	Deletion of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma progression by activating glucose metabolism and YAP signaling. *MedComm*, **2022**, 3,	2.2	1
35	Duo Cadherin-Functionalized Microparticles Synergistically Induce Chondrogenesis and Cartilage Repair of Stem Cell Aggregates.. *Advanced Healthcare Materials*, **2022**, e2200246	10.1	0
34	Altered glycosylation in pancreatic cancer and beyond.. *Journal of Experimental Medicine*, **2022**, 219,	16.6	0
33	The Role of Feedback Loops in Targeted Therapy for Pancreatic Cancer. *Frontiers in Oncology*, **2022**, 12,	5.3	0
32	Roles of Yes-associated protein and transcriptional coactivator with PDZ-binding motif in non-neoplastic liver diseases. *Biomedicine and Pharmacotherapy*, **2022**, 151, 113166	7.5	0
31	Interactions in CSF1-driven Tenosynovial Giant Cell Tumors.		0
30	PGM3 regulates beta-catenin activity to promote colorectal cancer cell progression. *Experimental Biology and Medicine*, 153537022211018	3.7	0
29	Histone methyltransferase Dot1L recruits O-GlcNAc transferase to target chromatin sites to regulate histone O-GlcNAcylation. *Journal of Biological Chemistry*, **2022**, 102115	5.4	0
28	O-GlcNAcylation: An Emerging Protein Modification Regulating the Hippo Pathway. *Cancers*, **2022**, 14, 3013	6.6	0
27	Ficolin-3 may act as a tumour suppressor by recognising O-GlcNAcylation site in hepatocellular carcinoma. *Medical Hypotheses*, **2022**, 110899	3.8	

26	N-glycosylation of GDF15 abolishes its inhibitory effect on EGFR in AR inhibitor-resistant prostate cancer cells. *Cell Death and Disease*, **2022**, 13,	9.8	1
25	Interactions in CSF1-driven Tenosynovial Giant Cell Tumors.		
24	Recent Advances Regarding the Molecular Mechanisms of Triterpenic Acids: A Review (Part II). **2022** , 23, 8896		0
23	Targeting O-GlcNAcylation to overcome resistance to anti-cancer therapies. 12,		0
22	Dysregulated FOXM1 signaling in the regulation of cancer stem cells. **2022**,		3
21	Role of O-GlcNAcylation on cancer stem cells: Connecting nutrient sensing to cell plasticity. **2022**,		0
20	Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine. **2022**, 12, 1544		0
19	The O-GlcNAcylation and its promotion to hepatocellular carcinoma. **2022**, 1877, 188806		2
18	The Emerging Roles of Protein Interactions with O-GlcNAc Cycling Enzymes in Cancer. **2022**, 14, 5135		0
17	D-galactose protects the intestine from ionizing radiation-induced injury by altering the gut microbiome.		0
16	Resveratrol inhibits proliferation and induces apoptosis via the Hippo/YAP pathway in human colon cancer cells. **2022**, 636, 197-204		1
15	The regulation and functions of ACSL3 and ACSL4 in the liver and hepatocellular carcinoma.		0
14	Inhibition of LATS Kinases in Ovarian Cancer Activates Cyclin D1/CDK4 and Decreases DYRK1A Activity.		0
13	PXR triggers YAP-TEAD binding and Sirt2-driven YAP deacetylation and polyubiquitination to promote liver enlargement and regeneration in mice. **2023**, 106666		0
12	FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. **2023**, 100926		0
11	Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression. **2023**, 14,		1
10	The role of metabolic reprogramming in pancreatic cancer chemoresistance. 13,		0
9	O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma.		0

8	KIAA1199 promotes oxaliplatin resistance and epithelial mesenchymal transition of colorectal cancer via protein O-GlcNAcylation. **2023**, 28, 101617	0
7	Emerging Role of Protein O-GlcNAcylation in Liver Metabolism: Implications for Diabetes and NAFLD. **2023**, 24, 2142	0
6	O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. **2023**, 8,	0
5	The Essential Role of O-GlcNAcylation in Hepatic Differentiation.	0
4	Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review. **2023**, 8,	0
3	Glucose metabolism of TAMs in tumor chemoresistance and metastasis. **2023**,	0
2	The Hexosamine Biosynthesis Pathway: Regulation and Function. **2023**, 14, 933	0
1	LncRNA modulates Hippo-YAP signaling to reprogram iron metabolism. **2023**, 14,	0